5-Bromocytosine
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
2240-25-7Nc1[nH]c(=O)ncc1BrQFVKLKDEXOWFSL-UHFFFAOYSA-N2240-25-7DTXSID60176932CHEMBL184965化学的特性LIGHT YELLOW AMORPHOUS POWDER
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
使用4-Amino-5-bromo-2-hydroxypyrimidine can be used in the synthesis of cross-link products under anaerobic and aerobic conditions.
一般的な説明5-Bromocytosine derivative (β isomer) is a potent anti-HIV agent.
純化方法5-Bromocytosine is recrystallised from H2O or 50% aqueous EtOH. Alternatively, dissolve ca 3g in conc HCl (10mL) and evaporate to dryness. Dissolve the residual hydrochloride in the minimum volume of warm H2O and make faintly alkaline with aqueous NH3. Collect the crystals and dry them in a vacuum at 100o. [Hilbdert & Jensen J Am Chem Soc 56 134 1934, Beilstein 25 III/IV 3689.]